About Celltrion
Celltrion is a publicly listed company based in Incheon (South Korea) founded in 2002. It operates as an antibody biosimilars for autoimmune diseases are developed. The company has 2,900 employees. Celltrion has completed 1 acquisition, including iQone Healthcare Group. Its chief executive is Woo-Sung Kee. Its website celltrion.com draws about 179 thousand monthly visits. Celltrion offers products and services including Biosimilars and R&D Services. Its focus areas include Traditional Pharmaceuticals and Biosimilars. Its legal entity in India is Celltrion Healthcare India Private Limited (U51101MH2011FTC212042).
Company details
Founded in 2002 in Incheon, South Korea, the company operates in the biotechnology sector, focusing on antibody biosimilars. Rensima, a biosimilar to infliximab, is utilized for treating rheumatoid arthritis and other autoimmune conditions. Additional biosimilars in development include versions of rituximab, adalimumab, bevacizumab, palivizumab, cetuximab, and etanercept. In 2020, annual revenues of 1.6 billion and net profit of 433.3 million were recorded.
- Headquarters Incheon, South Korea
- Employees 2,900
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website celltrion.com/en-us
- Social LinkedIn X Facebook Instagram
- Legal Name Celltrion, Inc.
- Annual Revenue$2.88 B (USD)17.01as on Dec 31, 2025
- Net Profit$713.2 M (USD)143.58as on Dec 31, 2025
- EBITDA$1 B (USD)59.52as on Dec 31, 2025
- Investors
- Employee Count2,900
- Investments & Acquisitions
Associated legal entities of Celltrion
Celltrion operates through Celltrion Healthcare India Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Celltrion Healthcare India Private Limited CIN U51101MH2011FTC212042 | Strike Off | 09 Jan 2011 | Mumbai, Maharashtra | – | – | 2 | View details |
Products & Services of Celltrion
Celltrion offers a comprehensive portfolio of products and services, including Biosimilars and R&D Services.
Biosimilars are developed and manufactured for various therapeutic areas such as immunology and oncology.
R&D services are provided for biopharmaceutical development, including clinical trials and regulatory affairs.
Funding Insights of Celltrion
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Celltrion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2010 | – | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Celltrion
Celltrion has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore |
Investor details for Celltrion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Celltrion Healthcare India Private Limited (Celltrion)
Celltrion Healthcare India Private Limited is the primary company behind Celltrion. The board of Celltrion Healthcare India Private Limited currently have 2 directors; the longest-serving is Kwang Young Moon, appointed in 2011.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kwang Young Moon DIN 03280818 | Director | 09 Jan 2011 | 15 yrs 9 mo | Celltrion Healthcare India Private Limited |
| Jong Hun Sung DIN 03280852 | Director | 09 Jan 2011 | 15 yrs 9 mo | Celltrion Healthcare India Private Limited |
People of Celltrion
2 people are tracked at Celltrion (1 in leadership, 1 in team); the tracked headcount is 2,900.
| Name | Role | Group |
|---|---|---|
Woo-Sung Kee | CEO & President | Leadership |
현구 여 | Assistant Manager | Team |
Complete people profiles for Celltrion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Celltrion
Celltrion is a publicly listed company on the KRX with ticker symbol 068270 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Jul 2017
- Listed onKOSDAQ: 91990
- Listed entityCelltrion, Inc.
- Exchange sectorHealth technology
- ISINKR7068270008
- Share price179,800.00 KRW (+0.06% on the day) · 2026-10-14
- Market capitalisation39,784,569,845,581.00 KRW
- Price to earnings26.3
- EPS (diluted, trailing year)6,829.56 KRW
- Dividend yield0.4%
- Volume (last session)462,644
Financials of Celltrion
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4,160.00B KRW | 1,030.00B KRW | 1,450.00B KRW |
| 2024 | 3,560.00B KRW | 422.69B KRW | 910.26B KRW |
| 2023 | 2,180.00B KRW | 535.65B KRW | 897.11B KRW |
| 2022 | 2,280.00B KRW | 529.50B KRW | 822.49B KRW |
| 2021 | 1,890.00B KRW | 579.46B KRW | 958.32B KRW |
Balance sheet, profit and loss, cash flow and ratios of Celltrion Healthcare India Private Limited are on its company page.
Detailed financial statements for Celltrion
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celltrion
Celltrion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include iQone Healthcare Group.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of biosimilar and breakthrough medicines distribution | iqone-healthcare.com | Versoix, Switzerland | 1979 | Nov 2024 | •••• |
Complete acquisition details for Celltrion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Celltrion
4 dated milestones of Celltrion across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Celltrion is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires iQone Healthcare Group.
Web traffic of Celltrion
The website of Celltrion (celltrion.com) receives about 179.3K visits a month and ranks #287,455 among all websites worldwide, #231 in Biotechnology and Pharmaceuticals.
- Monthly visits179.3K
▲ 57.8% vs previous month
- Unique visitors32.8K
per month
- Global rank#287,455
among all websites
- Category rank#231
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit4.5
- Average visit1 min 33 sec
- DevicesDesktop 65% · Mobile 35%
Websites whose visitors overlap most with Celltrion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
celltrionhealthcare.com | celltrionhealthcare.com | 100% | – | – | – |
celltrionit.sharepoint.com | celltrionit.sharepoint.com | 79% | – | – | – |
| samsungbiologics.com | 75% | 52K | #483,833 | View details | |
| celltrionph.com | 71% | 25.7K | #311,220 | View details | |
| gabionline.net | 70% | – | #1,546,519 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 28 similar websites and full traffic analytics for Celltrion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 28 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
10 companies that operate in the same segment as Celltrion (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Celltrion
Complete news archive for Celltrion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celltrion
Celltrion was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Celltrion is headquartered in Incheon, South Korea.
Woo-Sung Kee is the current CEO of Celltrion.
Celltrion has 2,900 employees.
Annual revenue of Celltrion is $2.88B as on Dec 31, 2025.
Founded in 2002 in Incheon, South Korea, the company operates in the biotechnology sector, focusing on antibody biosimilars. Rensima, a biosimilar to infliximab, is utilized for treating rheumatoid arthritis and other autoimmune conditions. Additional biosimilars in development include versions of rituximab, adalimumab, bevacizumab, palivizumab, cetuximab, and etanercept. In 2020, annual revenues of 1.6 billion and net profit of 433.3 million were recorded.
Celltrion offers Biosimilars and R&D Services.
Yes, Celltrion is publicly traded on KRX under the ticker symbol 068270.
Celltrion has made 1 acquisition, including iQone Healthcare Group.
Celltrion has 1 investor. Key investors include Temasek.
Celltrion operates through Celltrion Healthcare India Private Limited.
The legal entities of Celltrion currently have 2 directors, including Kwang Young Moon, Jong Hun Sung.